The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 31, 2017

Filed:

Apr. 03, 2015
Applicant:

The University of North Carolina AT Chapel Hill, Chapel Hill, NC (US);

Inventors:

Xiaodong Wang, Chapel Hill, NC (US);

Stephen Frye, Chapel Hill, NC (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/90 (2006.01); A61K 31/519 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/505 (2006.01); A61K 31/551 (2006.01); A61K 31/55 (2006.01); A61K 31/5513 (2006.01); A61K 45/06 (2006.01); C07D 487/04 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 487/08 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/505 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/55 (2013.01); A61K 31/551 (2013.01); A61K 31/5513 (2013.01); A61K 45/06 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 487/04 (2013.01); C07D 487/08 (2013.01);
Abstract

Pyrazolopyrimidine compounds, methods of use, and processes for making compounds with anti-Mer tyrosine kinase activity comprising Formula I, II, III, IV, or a pharmaceutically acceptable composition, salt, isotopic analog, or prodrug thereof, are provided. The pyrazolopyrimidine compounds described herein have Mer tyrosine kinase (MerTK) inhibitory activity and are useful as anti-infective agents, immunostimulatory and immunomodulatory agents, anti-cancer agents (including against MerTK −/− tumors and ITD and TKD mutant forms of Acute Myeloid Leukemia (AML)), and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.


Find Patent Forward Citations

Loading…